News | August 11, 2021
Marksons Pharma PAT at Rs 62.6 cr. for Q1FY22
The company has tied up with OrbiMed as a financial partner for global reach
The company has tied up with OrbiMed as a financial partner for global reach
The profits were bolstered by the Boehringer Ingelheim MEK program income
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
The healthcare vertical is US-focused, has 35-plus clients and 24,000 employees across 34 locations in five countries
The drug is indicated for mild and transient episodes of heart block
India business contributes to a stellar performance
The company expects revenue growth of 10-15 per cent in the US
The transaction is expected to close in the Q4FY22
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Subscribe To Our Newsletter & Stay Updated
